The collaboration resulted in a more robust manufacturing process for the novel TRK inhibitor. Asymchem, a leading global contract development and manufacturing service provider, and AUM Biosciences...
XPOVIO® is the first and only exportin 1 (XPO1) inhibitor approved in Taiwan. Antengene Corporation Limited, a leading innovative, commercial-stage global biopharmaceutical company dedicated to...
The facility will enable Biosyngen to develop safe, effective, and affordable cell therapies benefiting patients worldwide. The inauguration ceremony of Biosyngen Pte. Ltd., (“Biosyngen”) joint...
Camsirubicin analogue expands Monopar’s therapeutic pipeline. Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed...
New research from Duke-NUS Medical School, and the Agency for Science, Technology and Research identifies chemotherapy-resistant cancers’ escape mechanism, which offers new anticancer treatment...
In a new study published in the Cell Research, Zhang Chen-Yu’'s group at Nanjing University reports that In vivo self-assembled small RNA is the new generation of RNAi therapeutics. The development...
Information presented at AHA's Scientific Sessions provides insights on protecting the heart at every stage of cancer treatment. Developments in cancer treatment and care have dramatically improved...
AUM Biosciences and Newsoara Biopharma announce partnership to co-develop up to six oncology drugs within AUM’s pipeline. Clinical-stage biopharmaceutical company, AUM Biosciences, focuses on...
Researchers from Duke-NUS Medical School studied the mechanisms behind virus tolerance of bats and found changes in regulation of caspase-1 and interleukin-1 beta (IL-1β) pathways, with potential...
New technology cuts down on cell culture time by half and uses more targeted cell sorting and purification methods, which may help to address the issue of insufficient blood supply faced by...
Announced in early September 2020, Biofourmis closes US$100 million Series C financing led by SoftBank Vision Fund 2, with participation by existing investors Openspace Ventures, MassMutual Ventures,...
Researchers from Chiba University, Duke-NUS Medical School and the Agency for Science, Technology and Research (A*STAR) uncover the mechanism behind the relationship between the Epstein-Barr virus...
